Skip to content
Homepage
Author:
Zymeworks Inc.
Posted Date:
March 30, 2026
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
Zymeworks Inc.
March 30, 2026
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
Zymeworks Inc.
March 30, 2026
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc.
March 24, 2026
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting
Zymeworks Inc.
March 18, 2026
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
Zymeworks Inc.
March 18, 2026
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Zymeworks Inc.
March 2, 2026
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
Zymeworks Inc.
March 2, 2026
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
Zymeworks Inc.
February 17, 2026
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc.
February 6, 2026
Prev
1
2
